Fatty liver disease affects more than 1 in 3 adults and often has no symptoms. A new drug developed with Tulane researchers ...

The University of Hong Kong (HKU) has launched a clinical trial for a gene-related therapy aimed at treating chronic ...

The FDA approved SIR-Spheres Y-90 resin microspheres for unresectable liver cancer, the only radioembolization approved in ...

Chennai: In a meaningful step towards transforming liver cancer care in India, Apollo Proton Cancer Centre (APCC), Chennai, ...

The FDA approved Y-90 resin microspheres for the treatment of unresectable hepatocellular carcinoma, according to a press ...

The University of Hong Kong’s Faculty of Medicine said on Thursday that one of its 41 drugs under clinical trials for Hepatitis B may provide a cure ...

A research team led by Prof. Hai Li from the Hefei Institutes of Physical Science, Chinese Academy of Sciences, has become the first to systematically ...

The hunt for a medical breakthrough has been caught up in the Trump administration's political assault on the university.

Approval was based on results from the DOORwaY90 trial, which demonstrated a 98.5% overall response rate and 100% local tumor control in patients treated with the SIR-Spheres Y-90 resin microspheres ...

As per the recent health updates, Shoaib shared that though Dipika has undergone a surgery, there is a high risk of cancer ...

The PALMARES-2 trial reveals that abemaciclib and ribociclib outperform palbociclib in real-world progression-free survival ...

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an immunotherapy drug) plus gemcitabine and cisplatin (GemCis, chemotherapy drugs) as the ...